ASX - By Stock
|
PER |
Re:
Where others have failed will Atl1102 succeed ?
|
|
Baremoney
|
1.0K |
364K |
7 |
18/10/21 |
18/10/21 |
ASX - By Stock
|
1.0K
|
364K
|
7
|
|
ASX - By Stock
|
PER |
Re:
Where others have failed will Atl1102 succeed ?
|
|
Baremoney
|
1.0K |
364K |
3 |
16/10/21 |
16/10/21 |
ASX - By Stock
|
1.0K
|
364K
|
3
|
|
ASX - By Stock
|
PER |
Re:
Sarepta and Nasdaq
|
|
Baremoney
|
8 |
3.9K |
3 |
14/10/21 |
14/10/21 |
ASX - By Stock
|
8
|
3.9K
|
3
|
|
ASX - By Stock
|
PER |
Re:
Sarepta and Nasdaq
|
|
Baremoney
|
8 |
3.9K |
6 |
14/10/21 |
14/10/21 |
ASX - By Stock
|
8
|
3.9K
|
6
|
|
ASX - By Stock
|
PER |
Re:
Where others have failed will Atl1102 succeed ?
|
|
Baremoney
|
1.0K |
364K |
23 |
13/10/21 |
13/10/21 |
ASX - By Stock
|
1.0K
|
364K
|
23
|
|
ASX - By Stock
|
PER |
Re:
Where others have failed will Atl1102 succeed ?
|
|
Baremoney
|
1.0K |
364K |
10 |
13/10/21 |
13/10/21 |
ASX - By Stock
|
1.0K
|
364K
|
10
|
|
ASX - By Stock
|
PER |
Re:
Ann: Positive feedback received on Paediatric Investigation Plan
|
|
Baremoney
|
221 |
80K |
28 |
06/10/21 |
06/10/21 |
ASX - By Stock
|
221
|
80K
|
28
|
|
ASX - By Stock
|
PER |
Re:
CD49d promotes disease progression in chronic lymphocytic leukemia
|
|
Baremoney
|
37 |
11K |
8 |
05/10/21 |
05/10/21 |
ASX - By Stock
|
37
|
11K
|
8
|
|
ASX - By Stock
|
PER |
Re:
Ann: Positive feedback received on Paediatric Investigation Plan
|
|
Baremoney
|
221 |
80K |
11 |
30/09/21 |
30/09/21 |
ASX - By Stock
|
221
|
80K
|
11
|
|
ASX - By Stock
|
PER |
Re:
Ann: Positive feedback received on Paediatric Investigation Plan
|
|
Baremoney
|
221 |
80K |
10 |
30/09/21 |
30/09/21 |
ASX - By Stock
|
221
|
80K
|
10
|
|
ASX - By Stock
|
PER |
Re:
Where others have failed will Atl1102 succeed ?
|
|
Baremoney
|
1.0K |
364K |
2 |
29/09/21 |
29/09/21 |
ASX - By Stock
|
1.0K
|
364K
|
2
|
|
ASX - By Stock
|
PER |
Re:
Where others have failed will Atl1102 succeed ?
|
|
Baremoney
|
1.0K |
364K |
0 |
29/09/21 |
29/09/21 |
ASX - By Stock
|
1.0K
|
364K
|
0
|
|
ASX - By Stock
|
PER |
Re:
Where others have failed will Atl1102 succeed ?
|
|
Baremoney
|
1.0K |
364K |
5 |
29/09/21 |
29/09/21 |
ASX - By Stock
|
1.0K
|
364K
|
5
|
|
ASX - By Stock
|
PER |
Re:
Where others have failed will Atl1102 succeed ?
|
|
Baremoney
|
1.0K |
364K |
5 |
29/09/21 |
29/09/21 |
ASX - By Stock
|
1.0K
|
364K
|
5
|
|
ASX - By Stock
|
PER |
Re:
Where others have failed will Atl1102 succeed ?
|
|
Baremoney
|
1.0K |
364K |
0 |
29/09/21 |
29/09/21 |
ASX - By Stock
|
1.0K
|
364K
|
0
|
|
ASX - By Stock
|
PER |
Re:
Where others have failed will Atl1102 succeed ?
|
|
Baremoney
|
1.0K |
364K |
13 |
29/09/21 |
29/09/21 |
ASX - By Stock
|
1.0K
|
364K
|
13
|
|
ASX - By Stock
|
PER |
Re:
Where others have failed will Atl1102 succeed ?
|
|
Baremoney
|
1.0K |
364K |
13 |
29/09/21 |
29/09/21 |
ASX - By Stock
|
1.0K
|
364K
|
13
|
|
ASX - By Stock
|
NWE |
Re:
Ann: Lockyer Deep-1 Operational Update
|
|
Baremoney
|
336 |
154K |
7 |
27/09/21 |
27/09/21 |
ASX - By Stock
|
336
|
154K
|
7
|
|
ASX - By Stock
|
PER |
Re:
Ann: New data supports ATL1102s broader clinical potential
|
|
Baremoney
|
66 |
24K |
17 |
24/09/21 |
24/09/21 |
ASX - By Stock
|
66
|
24K
|
17
|
|
ASX - By Stock
|
PER |
Re:
Ann: ANP to present new proteomics data at WMS Congress 2021
|
|
Baremoney
|
108 |
37K |
4 |
23/09/21 |
23/09/21 |
ASX - By Stock
|
108
|
37K
|
4
|
|
ASX - By Stock
|
PER |
Re:
Ann: ANP to present new proteomics data at WMS Congress 2021
|
|
Baremoney
|
108 |
37K |
4 |
23/09/21 |
23/09/21 |
ASX - By Stock
|
108
|
37K
|
4
|
|
ASX - By Stock
|
PER |
Re:
Ann: ANP to present new proteomics data at WMS Congress 2021
|
|
Baremoney
|
108 |
37K |
1 |
22/09/21 |
22/09/21 |
ASX - By Stock
|
108
|
37K
|
1
|
|
ASX - By Stock
|
TPD |
Re:
Ann: Investor Presentation
|
|
Baremoney
|
116 |
33K |
2 |
15/09/21 |
15/09/21 |
ASX - By Stock
|
116
|
33K
|
2
|
|
ASX - By Stock
|
TPD |
Re:
Ann: Investor Presentation
|
|
Baremoney
|
116 |
33K |
7 |
15/09/21 |
15/09/21 |
ASX - By Stock
|
116
|
33K
|
7
|
|
ASX - By Stock
|
TPD |
Re:
Ann: Investor Presentation
|
|
Baremoney
|
116 |
33K |
5 |
15/09/21 |
15/09/21 |
ASX - By Stock
|
116
|
33K
|
5
|
|
ASX - By Stock
|
PER |
Re:
Where others have failed will Atl1102 succeed ?
|
|
Baremoney
|
1.0K |
364K |
1 |
10/09/21 |
10/09/21 |
ASX - By Stock
|
1.0K
|
364K
|
1
|
|
ASX - By Stock
|
PER |
Re:
Where others have failed will Atl1102 succeed ?
|
|
Baremoney
|
1.0K |
364K |
3 |
10/09/21 |
10/09/21 |
ASX - By Stock
|
1.0K
|
364K
|
3
|
|
ASX - By Stock
|
TPD |
Re:
Ann: RIU Good Oil Conference Presentation
|
|
Baremoney
|
59 |
21K |
5 |
10/09/21 |
10/09/21 |
ASX - By Stock
|
59
|
21K
|
5
|
|
ASX - By Stock
|
PER |
Re:
Ann: ANP Updates on US Regulatory Plans for ATL1102 in DMD
|
|
Baremoney
|
174 |
46K |
9 |
12/08/21 |
12/08/21 |
ASX - By Stock
|
174
|
46K
|
9
|
|
ASX - By Stock
|
PER |
Re:
Ann: Antisense Therapeutics transitions to new Board Chair
|
|
Baremoney
|
105 |
36K |
5 |
04/08/21 |
04/08/21 |
ASX - By Stock
|
105
|
36K
|
5
|
|
Charts
|
PER |
Re:
Chart
|
|
Baremoney
|
5.9K |
2.2M |
6 |
02/08/21 |
02/08/21 |
Charts
|
5.9K
|
2.2M
|
6
|
|
Charts
|
PER |
Re:
Chart
|
|
Baremoney
|
5.9K |
2.2M |
6 |
02/08/21 |
02/08/21 |
Charts
|
5.9K
|
2.2M
|
6
|
|
Charts
|
PER |
Re:
Chart
|
|
Baremoney
|
5.9K |
2.2M |
10 |
02/08/21 |
02/08/21 |
Charts
|
5.9K
|
2.2M
|
10
|
|
Charts
|
PER |
Re:
Chart
|
|
Baremoney
|
5.9K |
2.2M |
8 |
02/08/21 |
02/08/21 |
Charts
|
5.9K
|
2.2M
|
8
|
|
ASX - By Stock
|
PER |
Re:
Here’s ANP new board chair discussing why she joined the board
|
|
Baremoney
|
10 |
3.0K |
1 |
29/07/21 |
29/07/21 |
ASX - By Stock
|
10
|
3.0K
|
1
|
|
ASX - By Stock
|
PER |
Re:
Where others have failed will Atl1102 succeed ?
|
|
Baremoney
|
1.0K |
364K |
8 |
27/07/21 |
27/07/21 |
ASX - By Stock
|
1.0K
|
364K
|
8
|
|
ASX - By Stock
|
PER |
Re:
Where others have failed will Atl1102 succeed ?
|
|
Baremoney
|
1.0K |
364K |
11 |
27/07/21 |
27/07/21 |
ASX - By Stock
|
1.0K
|
364K
|
11
|
|
ASX - By Stock
|
PER |
Re:
Atl1102 a Blockbuster drug .
|
|
Baremoney
|
8 |
2.8K |
6 |
26/07/21 |
26/07/21 |
ASX - By Stock
|
8
|
2.8K
|
6
|
|
ASX - By Stock
|
PER |
Re:
Where others have failed will Atl1102 succeed ?
|
|
Baremoney
|
1.0K |
364K |
15 |
26/07/21 |
26/07/21 |
ASX - By Stock
|
1.0K
|
364K
|
15
|
|
ASX - By Stock
|
PER |
Re:
Ann: ANP and MCRI new R&D collaboration for ATL1102
|
|
Baremoney
|
287 |
92K |
5 |
21/07/21 |
21/07/21 |
ASX - By Stock
|
287
|
92K
|
5
|
|
ASX - By Stock
|
PER |
Re:
Trial timing
|
|
Baremoney
|
67 |
20K |
4 |
06/07/21 |
06/07/21 |
ASX - By Stock
|
67
|
20K
|
4
|
|
ASX - By Stock
|
PER |
Re:
Ann: ANP and MCRI new R&D collaboration for ATL1102
|
|
Baremoney
|
287 |
92K |
2 |
06/07/21 |
06/07/21 |
ASX - By Stock
|
287
|
92K
|
2
|
|
ASX - By Stock
|
PER |
Re:
Ann: ANP and MCRI new R&D collaboration for ATL1102
|
|
Baremoney
|
287 |
92K |
4 |
04/07/21 |
04/07/21 |
ASX - By Stock
|
287
|
92K
|
4
|
|
ASX - By Stock
|
PER |
Re:
Ann: ANP and MCRI new R&D collaboration for ATL1102
|
|
Baremoney
|
287 |
92K |
4 |
30/06/21 |
30/06/21 |
ASX - By Stock
|
287
|
92K
|
4
|
|
ASX - By Stock
|
PER |
Re:
Ann: ANP and MCRI new R&D collaboration for ATL1102
|
|
Baremoney
|
287 |
92K |
23 |
28/06/21 |
28/06/21 |
ASX - By Stock
|
287
|
92K
|
23
|
|
ASX - By Stock
|
PER |
Re:
Ann: US FDA Feedback on Type C Meeting for ATL1102 in the US
|
|
Baremoney
|
191 |
58K |
7 |
12/06/21 |
12/06/21 |
ASX - By Stock
|
191
|
58K
|
7
|
|
ASX - By Stock
|
PER |
Re:
Ann: US FDA Feedback on Type C Meeting for ATL1102 in the US
|
|
Baremoney
|
191 |
58K |
18 |
12/06/21 |
12/06/21 |
ASX - By Stock
|
191
|
58K
|
18
|
|
ASX - By Stock
|
PER |
Re:
Ann: US FDA Feedback on Type C Meeting for ATL1102 in the US
|
|
Baremoney
|
191 |
58K |
13 |
11/06/21 |
11/06/21 |
ASX - By Stock
|
191
|
58K
|
13
|
|
ASX - By Stock
|
PER |
Re:
Ann: US FDA Feedback on Type C Meeting for ATL1102 in the US
|
|
Baremoney
|
191 |
58K |
4 |
10/06/21 |
10/06/21 |
ASX - By Stock
|
191
|
58K
|
4
|
|
ASX - By Stock
|
PER |
Re:
Ann: US FDA Feedback on Type C Meeting for ATL1102 in the US
|
|
Baremoney
|
191 |
58K |
6 |
09/06/21 |
09/06/21 |
ASX - By Stock
|
191
|
58K
|
6
|
|